<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222091</url>
  </required_header>
  <id_info>
    <org_study_id>SU-10062010-7050</org_study_id>
    <nct_id>NCT01222091</nct_id>
  </id_info>
  <brief_title>Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids</brief_title>
  <official_title>Effect of Beta Blockade on Opioid-Induced Hyperalgesia in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      This research study explores whether a beta-blocker can prevent a person from becoming more
      sensitive to pain after administration of an opioid. Beta blockers inhibit the sympathetic
      (fight or flight) response and are often used to treat angina and high blood pressure. In a
      previous study in human volunteers, the investigators demonstrated an increased sensitivity
      to pain after a 60-minute infusion of the opioid remifentanil. The goal of this study is to
      identify a possible inhibitor of this phenomenon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent evidence suggests that opioid therapy may cause a biphasic response, i.e. initial pain
      relief followed paradoxically by a longer lasting hypersensitivity to pain. Recent genetic
      analysis in mice suggests that beta adrenergic receptor antagonists reduce opiate-induced
      hyperalgesia (OIH). The purpose of this study is to determine the analgesic and
      antihyperalgesic properties of the beta-blocker propranolol on remifentanil-induced
      hypersensitivity in humans.

      The investigators want to determine the analgesic and antihyperalgesic properties of the
      beta-blocker propranolol on remifentanil-induced hypersensitivity in humans. The
      investigators hope to learn whether the administration of beta-blocker propranolol will
      significantly diminish the hyperalgesic response after administration of an opioid.

      The primary outcome measure for this study is change in size (area) of secondary hyperalgesia
      after cessation of remifentanil infusion, a measure of OIH.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure for this study is change in size (area) of secondary hyperalgesia after cessation of remifentanil infusion, a measure of OIH.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective opioid withdrawal scale and objective opioid withdrawal scale</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperalgesia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men,

          2. Age between 18 and 45 years

          3. Normal weight (according to the table provided by Metropolitan Life Insurance).

        Exclusion Criteria:

          1. Hypersensitivity to opioids or naloxone,

          2. History of addictive disease,

          3. Significant cardiac, respiratory, gastrointestinal, neurological, dermatological, and
             psychiatric diseases,

          4. Concurrent medication with an analgesic drug,

          5. Student and employees affiliated with our laboratory
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Larry Fu-nien Chu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Larry Chu, MD, MS</last_name>
    <phone>(650) 723-5439</phone>
    <email>lchu@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Chu, MD, MS</last_name>
      <phone>650-723-5439</phone>
      <email>lchu@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tony Cun, BS</last_name>
      <phone>(916) 273-0404</phone>
      <email>tcun@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Larry Fu-nien Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chia YY, Liu K, Wang JJ, Kuo MC, Ho ST. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth. 1999 Sep;46(9):872-7.</citation>
    <PMID>10490157</PMID>
  </reference>
  <reference>
    <citation>Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, Fletcher D, Chauvin M. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000 Aug;93(2):409-17.</citation>
    <PMID>10910490</PMID>
  </reference>
  <reference>
    <citation>Larcher A, Laulin JP, Celerier E, Le Moal M, Simonnet G. Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience. 1998 May;84(2):583-9.</citation>
    <PMID>9539228</PMID>
  </reference>
  <reference>
    <citation>Laulin JP, Larcher A, Célèrier E, Le Moal M, Simonnet G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci. 1998 Feb;10(2):782-5.</citation>
    <PMID>9749743</PMID>
  </reference>
  <reference>
    <citation>Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002 May;94(5):1263-9, table of contents.</citation>
    <PMID>11973202</PMID>
  </reference>
  <reference>
    <citation>Li X, Angst MS, Clark JD. Opioid-induced hyperalgesia and incisional pain. Anesth Analg. 2001 Jul;93(1):204-9.</citation>
    <PMID>11429366</PMID>
  </reference>
  <reference>
    <citation>Célèrier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci. 2001 Jun 1;21(11):4074-80.</citation>
    <PMID>11356895</PMID>
  </reference>
  <reference>
    <citation>Compton P, Charuvastra VC, Kintaudi K, Ling W. Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manage. 2000 Oct;20(4):237-45.</citation>
    <PMID>11027904</PMID>
  </reference>
  <reference>
    <citation>Liang DY, Liao G, Wang J, Usuka J, Guo Y, Peltz G, Clark JD. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology. 2006 May;104(5):1054-62.</citation>
    <PMID>16645459</PMID>
  </reference>
  <reference>
    <citation>Tröster A, Sittl R, Singler B, Schmelz M, Schüttler J, Koppert W. Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans. Anesthesiology. 2006 Nov;105(5):1016-23.</citation>
    <PMID>17065897</PMID>
  </reference>
  <reference>
    <citation>Shafer SL, Varvel JR, Aziz N, Scott JC. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology. 1990 Dec;73(6):1091-102.</citation>
    <PMID>2248388</PMID>
  </reference>
  <reference>
    <citation>Drover DR, Lemmens HJ. Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. Anesthesiology. 1998 Oct;89(4):869-77.</citation>
    <PMID>9778004</PMID>
  </reference>
  <reference>
    <citation>Schmelz M, Schmid R, Handwerker HO, Torebjörk HE. Encoding of burning pain from capsaicin-treated human skin in two categories of unmyelinated nerve fibres. Brain. 2000 Mar;123 Pt 3:560-71.</citation>
    <PMID>10686178</PMID>
  </reference>
  <reference>
    <citation>Koppert W, Dern SK, Sittl R, Albrecht S, Schüttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology. 2001 Aug;95(2):395-402.</citation>
    <PMID>11506112</PMID>
  </reference>
  <reference>
    <citation>Avram MJ, Krejcie TC, Henthorn TK, Niemann CU. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution. J Pharmacol Exp Ther. 2004 Nov;311(2):617-24. Epub 2004 Jun 14.</citation>
    <PMID>15197245</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>October 15, 2010</last_update_submitted>
  <last_update_submitted_qc>October 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Larry Fu-nien Chu</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 9, 2016</submitted>
    <returned>March 7, 2016</returned>
    <submitted>November 16, 2016</submitted>
    <returned>January 12, 2017</returned>
    <submitted>January 18, 2017</submitted>
    <returned>March 8, 2017</returned>
    <submitted>August 29, 2017</submitted>
    <returned>September 26, 2017</returned>
    <submitted>May 15, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

